الفهرس | Only 14 pages are availabe for public view |
Abstract 1 INTRODUCTION General Introduction Since their introduction in the early 1960’s oral contraceptives have became widely accepted as a highly reliable method of family planning. While the piles efficacy has never been a contentious issue, its side effects and safety have been of concern to health professionals and their patients. This concern has resulted in the development of new formulations that contain reduced dosages of progestogen and oestrogen. Initially, attention was centered on reducing the oestrogen dosage because of its link to various side effects such as thrombolism, cardiovascular diseases and gastro-intestinal manifestations. More recently attention has tanned to lOwering the progestational potency of the pill, as studies found a link between progestagens and hypertension, reduction of glucose tolerance and reduction of high-density lipoprotein (HDL) cholesterol and arteriosclerosis (Dickey and Stone, 1980). The drug on which this present study has been centered is Norminest Fe. This low dose oral contraceptive was developed to 2 minimize serious side effects while maintaining efficacy, safety and 035 patient acceptance. Its formulation of 0.5 mg norethindrone and · of mg ethanol oestradiol represents the lowest effective dosB oestrogen combined with a low-potency progesterone (DickeY and Stone, 1980). . n nas As demonstrated in various clinical trials this combinatJO been claimed to be an effective and well-tolerated low dose oral contraceptive, because of this assumption as well as the increasinglY jiable dependency on contraceptive pills as one of the most highlY re method of family planning, the effect of the drug has subjected to investigation in this present study. |